1. Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy.
- Author
-
Shafaati T and Gopal K
- Subjects
- Humans, Animals, Forkhead Box Protein O1 metabolism, Forkhead Transcription Factors metabolism, Forkhead Transcription Factors antagonists & inhibitors, Forkhead Transcription Factors genetics, Oxidative Stress drug effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism, Diabetic Cardiomyopathies metabolism, Diabetic Cardiomyopathies drug therapy
- Abstract
Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Shafaati and Gopal.)
- Published
- 2024
- Full Text
- View/download PDF